-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
A microfluidic model for evaluating BBB penetration for GBM
Time of Update: 2022-09-21
of the Massachusetts Institute of Technology in the United States applied tumor globules culture, three-dimensional vascular mesh packets were cultured to construct models, and through confocal microscopy, living body chromochromatic localization imaging and in situ tumor loading, the role of the in vitro microfluidic model of vascular glioblastoma combined with the human blood-brain barrier model in the targeted nano-treatment of glioma was published in Proc Natl Acad, June 2022 Sci USA online.
-
JGH: Telomeres in Chinese populations of patients with IBS are significantly shortened
Time of Update: 2022-09-20
In addition, the researchers examined whether mental or psychological factors, IBS type, duration of IBS, and antidepressants were associated with LTL in IBS patients.
In addition, the researchers examined whether mental or psychological factors, IBS type, duration of IBS, and antidepressants were associated with LTL in IBS patients.
-
Immune Cell Research Guide: How B Cell Markers Are Selected
Time of Update: 2022-09-14
An overview of the major subtypes of B cells (image from Biocompare)Marker of B cell developmentMost B cells develop in the bone marrow (BM), followed by maturation in secondary lymphoid organs and eventually circulate in the bloodstream.
-
A large number of pharmaceutical companies want to take advantage of this model to achieve "curve overtaking" on the innovative drug track
Time of Update: 2022-09-07
License-in is a popular equity trading model in the domestic biomedical industry in recent years, and the reason why it is sought after by pharmaceutical companies is mainly because on the high-risk and high-input innovative drug track, this is a shortcut with less investment, fast effect, and even "curve overtaking".
-
Suntech's first launch of Suntech Pharmaceuticals completed hundreds of millions of yuan in Series C financing to promote the development of a new generation of brain disease treatment drugs
Time of Update: 2022-05-29
"Since the results of the clinical trial of the company's ACT001 drug in the treatment of DIPG (diffuse intrinsic pontine glioma in children) were presented in the form of a report at the SNO meeting in June 2021, we have received reports from around the world including Hong Kong, California and Utah.
-
BeiGene's CD3/CD19 Dual Antibody Belintoumumab New Indication Approved
Time of Update: 2022-05-14
Article source: Medical Cube InfoAuthor: infoOn April 29, BeiGene's new indication of belintoumumab for injection submitted by BeiGene was approved by the State Food and Drug Administration for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adults and children .
-
FDA issues draft regulatory guidance for antibody conjugated drugs, these points deserve attention
Time of Update: 2022-05-03
When developing ADC molecules, in vitro drug interaction analysis needs to be incorporated to understand the potential risks of unconjugated payloads and active metabolites .
-
Study shows long-term safety of genetically modified immune effector cells
Time of Update: 2022-04-22
A new study by researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine shows that patients receiving genetically modified immune cells ( IECs)-treated cancer patients did not have an increased risk of subsequent malignancies .
-
The next generation of BRAF inhibitors into the brain
Time of Update: 2022-01-12
ABM-1310, developed by Bichen Pharmaceutical, has shown its ideal advantages in blood-brain barrier penetration in pre-clinical studies .
-
The 71-year-old man with acute back pain, the story behind the "back" is not simple... The wind list is finalized
Time of Update: 2021-10-22
The patient has aortic dissection accompanied by the formation of giant cell granuloma of the ascending aorta.
GCA is a necrotizing arteritis of unknown cause, mainly invading the aorta and centering on elastin in the inner layer of the blood vessel, accompanied by granuloma formation, infiltration of lymphocytes, macrophages, and multinucleated giant cells, generally without fibrinous Necrosis .
-
Immunity found that immune cells can protect frequent sites where cancer spreads
Time of Update: 2021-10-01
Mary Jo Turk, co-director of the immunology and cancer immunotherapy research program at Dartmouth University and the Norris Cotton Cancer Center (NCCC) at Dartmouth-Hitchcock University I have been studying the immunity of metastatic cancer in the lymph nodes for the past year .
-
never expected! Science: The relationship between the intestinal immune system and nutrition is so close
Time of Update: 2021-03-27
In addition, studies have shown that the remodeling of intestinal epithelial cells occurs during the reaction to certain infections, which may also be the basis for their adaptation to different nutrients.
-
JAMA: Blinatumomab vs chemotherapy for children, adolescents and young patients with B-cell acute lymphoblastic leukemia who have relapsed for the first time
Time of Update: 2021-03-19
For children, adolescents, and young patients who have relapsed for the first time in B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improves patients The effects of disease-free survival and 2-year survival are not significant.
